Cyclo Therapeutics, Inc. - CYTH STOCK NEWS

Cyclo Therapeutics (NASDAQ: CYTH) is participating in Niemann-Pick Disease Awareness Month to raise awareness of Niemann-Pick Disease (NPC), a rare genetic disorder impacting 1 in 100,000 live births. The company emphasizes the need for treatment options and support for affected families. Cyclo Therapeutics is actively advancing its pivotal Phase 3 clinical trial, TransportNPC™, and has launched NPCspotlight.com for additional information. The CEO highlights the urgency of research and community support.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that its abstract has been chosen for poster presentation at the 14th International Congress of Inborn Errors of Metabolism in Sydney, Australia, from November 21-24, 2021. The poster will highlight the TransportNPC Phase 3 global trial of Trappsol® Cyclo™ for patients with Niemann-Pick disease type C1 (NPC1). This trial aims to evaluate safety and efficacy in a multicenter study involving at least 93 patients across 9 countries. The study duration is 96 weeks, including an interim analysis at 48 weeks.

Cyclo Therapeutics (NASDAQ: CYTH) announced its participation in the 2021 Virtual Cyclodextrin Conference on October 11, 2021, at 4:30 PM CET / 10:30 AM EST. Chief Scientific Officer Sharon H. Hrynkow will join a roundtable with key opinion leaders discussing cyclodextrins. The company’s treatment, Trappsol® Cyclo™, is undergoing a Phase 3 trial for Niemann-Pick Disease Type C and plans to file an IND for Alzheimer's treatment by year-end. Visit cyclotherapeutics.com for details.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced the appointment of Dr. Lise Lund Kjems as Chief Medical Officer, effective immediately. Dr. Kjems brings over 20 years of experience in drug development, particularly in rare diseases and oncology, previously holding leadership roles at major pharmaceutical companies like Novartis and Johnson & Johnson. Dr. Gerald F. Cox, previously Acting CMO, will now serve on the Scientific Advisory Board. The company anticipates Dr. Kjems' expertise will enhance clinical operations and support ongoing trials for Trappsol® Cyclo™, particularly in Niemann-Pick Disease Type C and Alzheimer’s Disease.

Cyclo Therapeutics (NASDAQ: CYTH) announced a live webcast presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET. CEO N. Scott Fine and CSO Sharon Hrynkow will present and engage in virtual one-on-one meetings with investors. The presentation will be accessible on the Company’s website and archived for 90 days. Cyclo Therapeutics focuses on developing treatments for diseases, including their orphan drug Trappsol^® Cyclo™ for Niemann-Pick Disease Type C.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company is focused on developing innovative treatments for diseases, particularly Niemann-Pick Disease Type C. A video webcast of the presentation will be available on-demand starting September 13, 2021. Cyclo Therapeutics is advancing its product Trappsol® Cyclo™, currently in multiple clinical trials, and plans to initiate early-phase Alzheimer’s Disease trials based on promising data.

Cyclo Therapeutics (Nasdaq: CYTH) reported its Q2 2021 financial results, highlighting positive topline results from its Phase 1/2 NPC study and the initiation of a pivotal Phase 3 NPC study. The net loss for the quarter was approximately $3.6 million, with R&D expenses increasing by 54% to $2.6 million due to heightened clinical activities. The company commenced commercial-scale manufacturing of Trappsol® Cyclo™ and received positive FDA feedback for its Alzheimer's program, planning an IND submission for a Phase 2 study by year-end 2021. Cash reserves stood at $11.4 million.

Cyclo Therapeutics (Nasdaq: CYTH) has released new data from its Phase 1 extension study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC). Presented at key medical conferences, the study shows a favorable safety profile with no drug-related adverse events. Clinically, 8 patients demonstrated disease stabilization over a mean exposure of 25 months, with some notable improvements in specific symptoms, despite some regressions in others. The company is advancing to pivotal Phase 3 trials, having received Orphan Drug and Fast Track designations from the FDA.

Cyclo Therapeutics (Nasdaq: CYTH) has announced the commercial-scale production of Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin formulation. This manufacturing milestone supports ongoing clinical trials for Niemann-Pick Disease Type C1 and Alzheimer’s disease. The company has received Orphan Drug Designation for Trappsol® Cyclo™ in the US and EU, alongside Fast Track and Rare Pediatric Disease Designations. Cyclo Therapeutics aims to file an IND for a Phase 2 study in Alzheimer’s treatment by late 2021.